Cantor Fitzgerald Reiterates Overweight Rating, $12 Price Target on Lucid Diagnostics Inc (LUCD) on BeiGene's RATIONALE 306 Trial Data, "Encourage Investors to Acquire LUCD Shares at an Attractive Ent
Tweet Send to a Friend
Cantor Fitzgerald analyst Ross Osborn reiterated an Overweight rating and $12.00 price target on Lucid Diagnostics Inc (NASDAQ: LUCD) on ...
This is a premium only article. To continue reading this and other premium stock market news articles please sign-in or upgrade to StreetInsider.com Premium below (Free Trial) LEARN MORE
This is a premium only article. To continue reading this and other premium stock market news articles please sign-in or upgrade to StreetInsider.com Premium below (Free Trial) LEARN MORE
